# P3-PROSE-DEPTH-1 — Prose Library Depth and Modifier Schema

**Work ID:** P3-PROSE-DEPTH-1  
**Date closed:** 2026-06-29

## 1. Start state

P2-4 merged (`NarrativePayloadV1` hardened). Retail explainers at 40 entries; pathway pack at 5; missing-marker pack bootstrapped (6). Context modifier catalogue has 35 draft entries (all `runtime_active: false`). No MR candidate prose schema or coverage matrix existed.

## 2. Architecture authority reviewed

* `docs/planning-papers/DYNAMIC-PROSE-ARCH-1_dynamic_personalised_prose_architecture_review.md` — hybrid minimum viable composition confirmed
* `docs/audit-papers/PROSE-INVENTORY-1_prose_library_prose_to_ux_architecture_inventory_review.md` (path corrected from prompt)
* `P2-2+P2-3` and `P2-4` completion reports
* `BUILD_DELIVERABLE_REGISTER.md`

## 3. Existing assets found

* 40 retail biomarker explainers in `retail_explainer_v1/registry.yaml`
* 5 pathway explainers (homocysteine, lipid, iron, thyroid, renal)
* 6 missing-marker caveats
* 35 context modifiers (catalogued, not runtime-bound)
* 8 intervention classes in effects registry
* 7 supplement modifier catalogue entries
* Partial signal/frame prose via interpretation entities and lead routing (iron, thyroid, homocysteine, lipid)

## 4. Coverage gaps identified

* 64 SSOT biomarkers without retail explainers (programme target ~79 base)
* Hepatic and metabolic/glycaemic pathway explainers missing
* Missing-marker gaps for hepatic, lipid (apob), metabolic contexts
* Modifier prose fragments absent (lifestyle, medication, supplement)
* Positive/resilience qualifiers absent as dedicated asset type
* Frame-level prose deferred (P2-FRAME-ROUTING-ARCHITECTURE-1)

## 5. Schema created

`P3-PROSE-DEPTH-1_mr_candidate_asset_schema.yaml` — MR candidate asset fields, allowed types, review statuses, safety rules, promotion discipline.

## 6. MR Batch 001 scope

Hepatic + metabolic pathway candidates; top 10 missing retail explainers; missing-marker candidates for hepatic/metabolic/lipid/kidney; lifestyle/medication/supplement modifier fragments per governed catalogues. Brief: `P3-PROSE-DEPTH-1_mr_batch_001_brief.md`.

## 7. Modifier template scope

`P3-PROSE-DEPTH-1_modifier_fragment_templates.yaml` — additive fragment structures, prohibited claims, conflict/suppression notes, destination placeholders.

## 8. What remains candidate-only

All MR Batch 001 targets, modifier fragments, pathway gaps, and retail gap fill — explicitly `CANDIDATE` / not runtime.

## 9. What requires medical review

Pathway candidates (hepatic/metabolic), high-value modifier fragments, missing-marker expansions, positive resilience qualifiers, any causation-adjacent wording.

## 10. What requires future runtime/promotion work

* MR Batch 001 execution and medical review
* Candidate → approved promotion/import route
* Modifier runtime binding
* Frame routing architecture
* P4-1 Gemini activation (CEO gate)

## 11. Recommended next sprint

**MR Batch 001 execution** (Medical Research LLM candidate generation) followed by medical review and a promotion/import sprint. Alternative: continued retail coverage tranche if programme decides full 79/79 is beta-blocking.

**pipeline_advisory_trigger:** true  
**pipeline_advisory_reason:** P3-PROSE-DEPTH-1 content-factory foundations complete; next work should be MR Batch 001 candidate generation, then medical review and promotion/import — not runtime or Gemini activation.
